Healthcare Analyst Santangelo discusses the current playbook around Bausch Health’s (BHC) Xifaxan litigation following Amneal Paragraph IV and Norwich ruling on an Analyst/Industry conference call to be held on April 17 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Wins Patent Appeal for XIFAXAN
- Bausch Health says ruling prevents FDA approval of Norwich ANDA until 2029
- Bausch ‘win’ in Xifaxan case clears major hurdle ahead of spin, says Jefferies
- Appeals court affirms ruling in Bausch Health-Norwich patent fight
- Bausch Health announces ARAZLO availability through BC PharmaCare
